Intercell AG Company Profile
Intercell AG is a fast growing biotechnology company with a clear strategy and focus on the design and development of novel vaccines for prevention and treatment of infectious diseases with substantial unaddressed medical need. The Company's unique position is based on the combination of antigens and immunizers (adjuvants) derived from its proprietary technology platforms and its in-house GMP manufacturing facilities. Intercell's technology has been endorsed by collaborative agreements with a number of global pharmaceutical companies, including sanofi pasteur, Merck&Co., Inc., SciGen Ltd. and the Statens Serum Institut. The Company has a broad development pipeline with a vaccine for Japanese Encephalitis undergoing Phase III clinical trials, a vaccine for Hepatitis C in Phase II trials, and five products focused on infectious diseases in the pre-clinical phase. Intercell is listed on the Vienna stock exchange under the symbol "ICLL".
Location
Campus Vienna Biocenter 6
Vienna
1030
Austria
Contact
Phone: 43 1 20 620 0
Fax: 43 1 20 620 300
Email: info@intercell.com
News Articles
Proposed Merger of Equals between Vivalis and Intercell - Creation of a European Biotech Leader ...
Vivalis (“Vivalis”) and Intercell AG (“Intercell”) to merge and form Valneva SE (“Valneva”), headquartered in Lyon (France) and listed on the regulated markets...
BRIEF-Intercell says proposed merger of equals with Vivalis
VIENNA, Dec 16 (Reuters) - Intercell AG : * Says proposed merger of equals between Vivalis and Intercell * Says Intercell shareholders to receive 13 Vivalis new ordinary shares for 40
Intercell-Aktie: Fusion mit Vivalis wird vorbereitet
Wien - Die Analystin von Erste Group Research, Vladimira Urbankova, stuft die Intercell-Aktie (ISIN AT0000612601/ WKN A0D8HW) mit "halten" ein.Intercell habe diese Woche wieder einmal für viel Aufr.....
Geplanter „Merger of Equals“ von Vivalis und Intercell – Bildung eines europaweit führenden Biotech-Unternehmens für Impfstoffe und Antikörper Verschmelzung von Vivalis (“Vivalis”) un...
EANS-News: Intercell AG / Intercell und Vivalis geben Update über Fortschritte des beabsichtigen Mergers -------------------------------------------------------------------------------- Corporate ...
BRIEF-Intercell sees full-year net loss of 20-24 mln eur
VIENNA, Oct 16 (Reuters) - Intercell AG : * Says preliminary third quarter close shows approximately EUR 18M
Intercell und Vivalis geben Update über Fortschritte des beabsichtigen Mergers
Nantes (Frankreich) und Wien (Österreich), 28. Jänner 2013 – Am 16. Dezember 2012 haben Vivalis SA (“Vivalis”) und Intercell AG (“Intercell”) die Absicht zur Verschmelzung und zur Bildung...
Wenn es fachlich bleibt und die User sich nicht permanent gegenseitig befetzen, bin ich ein Riesenfan des BE-Postingboards … - bezogen auf … -Intercell: "Aids-Impfstoff mit Intercells IC31 Adjuvan...
Drugs and Medications
None
PubMed Articles
Transcutaneous immunization with Intercell's vaccine delivery system.
Transcutaneous immunization (TCI) has become an attractive alternate route of immunization due to increase understanding of the skin immune system and to recent technical innovations in skin patch del...
IXIARO (IC51), a recently approved inactivated Japanese Encephalitis vaccine, is immunogenic and safe in a 0/28 days primary immunization schedule. Neutralizing antibody titers decline with time and b...
IC51 (IXIARO((R)), JESPECT((R))) is a recently approved prophylactic Japanese encephalitis virus vaccine with a two-vaccine primary immunization regimen. In this phase 3 trial, after primary immunizat...
Group B streptococcus is one of the most important pathogens in neonates, and causes invasive infections in non-pregnant adults with underlying diseases. Applying a genomic approach that relies on hum...
Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO(®).
Japanese encephalitis (JE) is the most common cause for viral encephalitis in Asia and can be effectively prevented by vaccination. IXIARO(®) is a Vero cell-derived, inactivated JE virus vaccine whic...
Clinical Trials
None
Companies
Intercell AG is a fast growing biotechnology company with a clear strategy and focus on the design and development of novel vaccines for prevention and treatment of infectious diseases with substantia...
Founded in October 2005, Pelias combines unique know-how and dedicated development expertise in the field of infectious diseases with advanced projects licensed from Chiron and Intercell. On the basis...
More Information about "Intercell AG" on BioPortfolio
We have published hundreds of Intercell AG news stories on BioPortfolio along with dozens of Intercell AG Clinical Trials and PubMed Articles about Intercell AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Intercell AG Companies in our database. You can also find out about relevant Intercell AG Drugs and Medications on this site too.
